文献速递神经肌肉病

依库珠单抗治疗难治性全身型重症肌无力的3期试验

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
PubMed 文献 · Lancet Neurol · 2017-10-20

REGAIN是一项3期随机双盲安慰剂对照多中心研究,纳入125例抗乙酰胆碱受体抗体阳性难治性全身型重症肌无力患者,评估依库珠单抗疗效与安全性。

要点

  • 依库珠单抗耐受性良好,未发生脑膜炎球菌感染或死亡。
  • 最差秩分析法可能掩盖次要分析中的获益信号,需进一步研究补体角色。

核心结论

  • 依库珠单抗与安慰剂相比,MG-ADL评分变化无统计学显著差异。
  • 依库珠单抗耐受性良好,但最差秩分析法是本研究的重要局限。

研究设计与样本

  • 3期随机双盲安慰剂对照多中心研究,在17个国家76家医院和专科诊所进行。
  • 纳入125例抗乙酰胆碱受体抗体阳性难治性全身型重症肌无力患者,随机1:1接受依库珠单抗或安慰剂治疗26周。

主要发现

  • 最常见不良事件为头痛和上呼吸道感染,依库珠单抗组各10例(16%),安慰剂组各12例(19%)。
  • 重症肌无力加重:依库珠单抗组6例(10%),安慰剂组15例(24%);需要挽救治疗:依库珠单抗组6例(10%),安慰剂组12例(19%)。
  • 研究期间无死亡或脑膜炎球菌感染病例。

关键数值与推荐

  • 入选标准:年龄≥18岁,MG-ADL评分≥6,MGFA II-IV级,接种脑膜炎奈瑟菌疫苗,且至少两种免疫抑制治疗或一种免疫抑制治疗联合慢性静脉注射免疫球蛋白或血浆置换12个月未控制症状。
  • 排除标准:胸腺瘤或胸腺肿瘤史,筛查前12个月内胸腺切除术,随机前4周内使用静脉注射免疫球蛋白或血浆置换,筛查前6个月内使用利妥昔单抗。

临床怎么用

  • 依库珠单抗在本研究主要分析中未显示显著优于安慰剂,但耐受性良好。
  • 最差秩分析法可能导致结果解读受限,临床决策需结合次要分析和敏感性分析。

局限性

  • 最差秩分析法被证明是本研究的重要局限,次要和敏感性分析结果与主要终点结果不一致。
  • 研究未达到主要终点,补体在难治性全身型重症肌无力中的作用需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complement is likely to have a role in refractory generalised myasthenia gravis, but no approved therapies specifically target this system. Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. We further assessed the efficacy and safety of eculizumab in this patient population in a phase 3 trial. METHODS: We did a phase 3, randomised, double-blind, placebo-controlled, multicentre study (REGAIN) in 76 hospitals and specialised clinics in 17 countries across North America, Latin America, Europe, and Asia. Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II-IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control. Patients with a history of thymoma or thymic neoplasms, thymectomy within 12 months before screening, or use of intravenous immunoglobulin or plasma exchange within 4 weeks before randomisation, or rituximab within 6 months before screening, were excluded. We randomly assigned participants (1:1) to either intravenous eculizumab or intravenous matched placebo for 26 weeks. Dosing for eculizumab was 900 mg on day 1 and at weeks 1, 2, and 3; 1200 mg at week 4; and 1200 mg given every second week thereafter as maintenance dosing. Randomisation was done centrally with an interactive voice or web-response system with patients stratified to one of four groups based on MGFA disease classification. Where possible, patients were maintained on existing myasthenia gravis therapies and rescue medication was allowed at the study physician's discretion. Patients, investigators, staff, and outcome assessors were masked to treatment assignment. The primary efficacy endpoint was the change from baseline to week 26 in MG-ADL total score measured by worst-rank ANCOVA. The efficacy population set was defined as all patients randomly assigned to treatment groups who received at least one dose of study drug, had a valid baseline MG-ADL assessment, and at least one post-baseline MG-ADL assessment. The safety analyses included all randomly assigned patients who received eculizumab or placebo. This trial is registered with ClinicalTrials.gov, number NCT01997229. FINDINGS: Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56·6 [SEM 4·5] vs 68·3 [4·5]; rank-based treatment difference -11·7, 95% CI -24·3 to 0·96; p=0·0698). No deaths or cases of meningococcal infection occurred during the study. The most common adverse events in both groups were headache and upper respiratory tract infection (ten [16%] for both events in the eculizumab group and 12 [19%] for both in the placebo group). Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy. INTERPRETATION: The change in the MG-ADL score was not statistically significant between eculizumab and placebo, as measured by the worst-rank analysis. Eculizumab was well tolerated. The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed. FUNDING: Alexion Pharmaceuticals.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017. PMID: 29066163. doi:10.1016/S1474-4422(17)30369-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。